PRMT6 (Protein Arginine Methyltransferase 6) is a member of the PRMT enzyme family that catalyzes the post-translational methylation of arginine residues in histones and non-histone proteins, playing a key role in epigenetic regulation. It primarily mediates asymmetric dimethylation of arginine (ADMA), notably on histone H3 at arginine 2 (H3R2me2a), which antagonizes trimethylation of H3K4 (H3K4me3), leading to transcriptional repression. PRMT6 is involved in diverse cellular processes, including DNA repair, chromatin remodeling, and immune response, and has been linked to diseases such as cancer, neurodegenerative disorders, and viral pathogenesis.
PRMT6-specific antibodies are critical tools for studying its expression, localization, and function in these contexts. They are widely used in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to assess PRMT6 protein levels, subcellular distribution, and interaction with substrates. Due to structural similarities among PRMT family members, high-quality PRMT6 antibodies must be rigorously validated for specificity, often using knockout cell lines or competitive peptides. Dysregulation of PRMT6 has been implicated in tumor progression (e.g., promoting prostate cancer metastasis) and HIV-1 replication (by methylating viral Tat protein), making its antibodies valuable for both basic research and therapeutic exploration. Recent studies also highlight PRMT6's role in cellular senescence and aging-related pathways, further driving demand for reliable detection reagents.